NASDAQ:MGLN - Magellan Health Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $93.33
  • Forecasted Upside: -0.60 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$93.90
▼ -0.06 (-0.06%)
1 month | 3 months | 12 months
Get New Magellan Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGLN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$93.33
▼ -0.60% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Magellan Health in the last 3 months. The average price target is $93.33, with a high forecast of $95.00 and a low forecast of $90.00. The average price target represents a -0.60% upside from the last price of $93.90.
Hold
The current consensus among 3 contributing investment analysts is to hold stock in Magellan Health. This rating has held steady since January 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$92.00 ➝ $95.00Low
i
1/6/2021StephensDowngradeOverweight ➝ Equal Weight$95.00N/A
i
11/13/2020StephensUpgradeEqual Weight ➝ Overweight$83.00 ➝ $98.00High
i
9/10/2020Bank of AmericaBoost Price TargetBuy$86.00 ➝ $90.00Low
i
7/30/2020Jefferies Financial GroupBoost Price TargetBuy$85.00 ➝ $96.00Medium
i
11/11/2019StephensReiterated RatingEqual Weight$65.00 ➝ $67.00Low
i
2/22/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$84.00High
i
1/14/2019StephensInitiated CoverageEqual ➝ Equal Weight$68.00High
i
11/13/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$90.00 ➝ $70.00High
i
Rating by A. Gupte at SVB Leerink LLC
11/12/2018Raymond JamesLower Price TargetOutperform ➝ Buy$85.00 ➝ $72.00Low
i
Rating by Michael J. Baker at Raymond James
7/30/2018Raymond JamesLower Price TargetOutperform ➝ Buy$105.00 ➝ $85.00Low
i
Rating by Michael J. Baker at Raymond James
5/1/2018Raymond JamesUpgradeMarket Perform ➝ OutperformMedium
i
Rating by Michael J. Baker at Raymond James
3/15/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformMedium
i
Rating by A. Gupte at SVB Leerink LLC
12/2/2017Raymond JamesReiterated RatingHoldHigh
i
Rating by Michael J. Baker at Raymond James
12/1/2017KeyCorpSet Price TargetBuy$105.00High
i
Rating by Jason Gurda at KeyCorp
10/13/2017Jefferies Financial GroupReiterated RatingBuy$94.00N/A
i
9/22/2017KeyCorpReiterated RatingBuy$89.00Low
i
7/13/2017KeyCorpUpgradeSector Weight ➝ Overweight$91.00High
i
6/25/2017SVB LeerinkReiterated RatingOutperform$68.00 ➝ $73.00Low
i
2/24/2017Jefferies Financial GroupLower Price TargetBuy$89.00 ➝ $88.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
12/23/2016Jefferies Financial GroupReiterated RatingBuy$89.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
11/28/2016SVB LeerinkReiterated RatingMarket Perform$60.00 ➝ $78.00N/A
i
Rating by Ana Gupte at SVB Leerink LLC
11/23/2016BarclaysBoost Price TargetUnderweight$61.00 ➝ $69.00N/A
i
11/18/2016Jefferies Financial GroupReiterated RatingBuy$78.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
10/15/2016Jefferies Financial GroupSet Price TargetBuy$76.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
9/26/2016Jefferies Financial GroupReiterated RatingBuy$86.00 ➝ $76.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
8/12/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Ana Gupte at SVB Leerink LLC
6/30/2016KeyCorpInitiated CoverageEqual WeightN/A
i
6/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
6/4/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Ana Gupte at SVB Leerink LLC
6/1/2016BarclaysDowngradeEqual Weight ➝ Underweight$61.00N/A
i
5/20/2016Jefferies Financial GroupReiterated RatingBuy$83.00 ➝ $86.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
5/6/2016Jefferies Financial GroupReiterated RatingBuy$77.00 ➝ $83.00N/A
i
Rating by David Styblo at Jefferies Financial Group Inc.
(Data available from 4/21/2016 forward)
Magellan Health logo
Magellan Health, Inc., together with its subsidiaries, provides healthcare management services in the United States. The company operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. It also contracts with state Medicaid agencies, and the centers for Medicare and Medicaid services to manage care for beneficiaries under Medicaid and Medicare programs, such as healthcare and long-term support services through its network of medical and behavioral health professionals, clinics, hospitals, nursing facilities, home care agencies, and ancillary service providers. The Pharmacy Management segment comprises products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. Further, it offers pharmacy benefit management services, such as pharmaceutical dispensing services; pharmacy benefit administration for state Medicaid and other government sponsored programs; clinical and formulary management programs; medical pharmacy management programs; and programs for the integrated management of specialty drugs that treat complex conditions. In addition, the company provides services to managed care organizations, employers, third party administrators, state governments, and other government agencies, exchanges, brokers, and consultants. Magellan Health, Inc. was incorporated in 1969 and is headquartered in Phoenix, Arizona.
Read More

Today's Range

Now: $93.90
$93.80
$94.19

50 Day Range

MA: $93.64
$92.82
$94.35

52 Week Range

Now: $93.90
$48.82
$95.43

Volume

144,870 shs

Average Volume

355,554 shs

Market Capitalization

$2.44 billion

P/E Ratio

17.62

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Magellan Health?

The following sell-side analysts have issued stock ratings on Magellan Health in the last year: Bank of America Co., Jefferies Financial Group Inc., Stephens, and Zacks Investment Research.
View the latest analyst ratings for MGLN.

What is the current price target for Magellan Health?

3 Wall Street analysts have set twelve-month price targets for Magellan Health in the last year. Their average twelve-month price target is $93.33, suggesting a possible downside of 0.6%. Stephens has the highest price target set, predicting MGLN will reach $95.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $90.00 for Magellan Health in the next year.
View the latest price targets for MGLN.

What is the current consensus analyst rating for Magellan Health?

Magellan Health currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MGLN, but not buy more shares or sell existing shares.
View the latest ratings for MGLN.

What other companies compete with Magellan Health?

Other companies that are similar to Magellan Health include UnitedHealth Group, Anthem, Cigna, Humana, Centene, Molina Healthcare and Triple-S Management.

How do I contact Magellan Health's investor relations team?

Magellan Health's physical mailing address is 4801 E. Washington Street, Phoenix AZ, 85034. The company's listed phone number is 800-642-1716 and its investor relations email address is [email protected] The official website for Magellan Health is www.magellanhealth.com.